Reason GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross…
Mylan Institutional, Inc. (d.b.a. UDL Laboratories)NDC 51079-903-20D-0823-2018
Reason GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross…
Mylan Institutional, Inc. (d.b.a. UDL Laboratories)NDC 51079-902-20D-0822-2018